Mostrar el registro sencillo del ítem

dc.contributor.authorCoba Lacle, José Antonio
dc.date.accessioned2020-02-17T16:30:07Z
dc.date.available2020-02-17T16:30:07Z
dc.date.issued2019
dc.identifier.urihttps://hdl.handle.net/20.500.12442/4756
dc.description.abstractLa Enfermedad de Fabry forma parte de las enfermedades ligadas a errores innatos del metabolismo, del subgrupo de enfermedades lisosomales; y se caracteriza por la deficiencia de la actividad de la enzima lisosomal llamada a-galactosidasa A (a-Gal A), enzima que interviene en el catabolismo de los glicoesfingolípidos. El defecto enzimático lleva a la acumulación de Globotriaosilceramida (GL-3) y de otros glicoesfingolípidos. Mediante la realización de una encuesta familiar se evaluó grado de autoconocimiento de los otros miembros de la familia que padece FD. Valorando de esta manera logramos estimar su calidad de vida mediante, estrato socioeconómico, nivel de educación, edad, género, profesiones. Además se presentan dos casos clínicos de pacientes que cursan con FD.spa
dc.description.abstractFabry's disease is part of the diseases linked to inborn errors of metabolism, of the subgroup of lysosomal diseases; and is characterized by a deficiency in the activity of the lysosomal enzyme called a-galactosidase A (a-Gal A), an enzyme that is involved in the catabolism of glycosphingolipids. The enzyme defect leads to the accumulation of Globotriaosylceramide (GL-3) and other glycosphingolipids. By conducting a family survey, the degree of self-knowledge of the other family members suffering from FD was evaluated. In this way, we estimate their quality of life through socioeconomic status, level of education, age, gender, professions. In addition, there are two clinical cases of patients with FD.eng
dc.format.mimetypepdfspa
dc.language.isospaspa
dc.publisherEdiciones Universidad Simón Bolívarspa
dc.publisherFacultad de Ciencias Básicas y Biomédicasspa
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectGlicoesfingolípidosspa
dc.subjectEnfermedad lisosomalspa
dc.subjectAlfagalactosidasaspa
dc.subjectSíndrome Fabry Andersonspa
dc.subjectLisosomaspa
dc.subjectEnfermedad De Fabryspa
dc.subjectFabryspa
dc.subjectGlycosphingolipidseng
dc.subjectLysosomal Diseaseeng
dc.subjectAlphagalactosidaseeng
dc.subjectFabry Anderson Syndromeeng
dc.subjectLysosomeeng
dc.subjectFabry Diseaseeng
dc.titleReporte de caso: familia que padece enfermedad de Fabry. Análisis de su expresión clínicaspa
dc.typeOtherspa
dcterms.referencesTeresa M, Martino D, Scionti F, Sestito S, Nicoletti A, Arbitrio M, et al. Genetic variants associated with gastrointestinal symptoms in Fabry disease. 2016;7(52):85895–904. zeng
dcterms.referencesMartins AM, D’Almeida V, Kyosen SO, Takata ET, Delgado AG, Gonçalves AMBF, et al. Guidelines to diagnosis and monitoring of Fabry disease and review of treatment experiences. J Pediatr. 2009;155(4 Suppl):S19–31.eng
dcterms.referencesToyooka K. Fabry disease [Internet]. 1st ed. Vol. 115, Handbook of Clinical Neurology. Elsevier B.V.; 2013. 629–642 p. Available from: http://dx.doi.org/10.1016/B978-0-444-52902-2.00037-0eng
dcterms.referencesVerstegen RHJ, Theodore M, van de Klerk H, Morava E. Lymphatic edema in congenital disorders of glycosylation. JIMD Rep. 2012;4(18):113–6.eng
dcterms.referencesRichter T, Nestler-Parr S, Babela R, Khan ZM, Tesoro T, Molsen E, et al. Rare Disease Terminology and Definitions-A Systematic Global Review: Report of the ISPOR Rare Disease Special Interest Group. Value Heal [Internet]. 2015;18(6):906–14. Available from: http://dx.doi.org/10.1016/j.jval.2015.05.008eng
dcterms.referencesENFERMEDADES HUERFANAS cuenta de alto costo colombia - https://cuentadealtocosto.org/site/index.php/patologias/9-patologias/24-enfermedades-huerfanas/?template=cuentadealtocostocontenido.spa
dcterms.referencesSchiffmann R, Fuller M, Clarke LA, Aerts JMFG. Is it Fabry disease? Genet Med [Internet]. 2016;(January):1–5. Available from: http://www.nature.com/doifinder/10.1038/gim.2016.55eng
dcterms.referencesThe Human Gene Mutation Database - GLA Gene [Internet]. [cited 2019 Feb 13]. Available from: http://www.hgmd.cf.ac.uk/ac/gene.php?gene=GLAeng
dcterms.referencesLidove O, Kaminsky P, Hachulla E, Leguy-Seguin V, Lavigne C, Marie I, et al. Fabry disease “The New Great Imposter”: Results of the French Observatoire in Internal Medicine Departments (FIMeD). Clin Genet. 2012;81(6):571–7.eng
dcterms.referencesSchiffmann R, Hughes DA, Linthorst GE, Ortiz A, Svarstad E, Warnock DG, et al. Screening, diagnosis, and management of patients with Fabry disease: conclusions from a “ Kidney Disease: Improving Global Outcomes ” (KDIGO) Controversies Conference. 2017;284–93.eng
dcterms.referencesCammarata G, Fatuzzo P, Rodolico MS, Colomba P, Sicurella L, Iemolo F, et al. High variability of Fabry Disease manifestations in an extended Italian family. Biomed Res Int. 2015;2015(June 2013).eng
dcterms.referencesMasson C, Cissé I, Simon V, Insalaco P, Audran M. Fabry disease: A review. Jt Bone Spine. 2004;71(5):381–3.eng
dcterms.referencesWaldek S, Patel MR, Banikazemi M, Lemay R, Lee P. Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry. Genet Med [Internet]. 2009;11(11):790–6. Available from: http://dx.doi.org/10.1097/GIM.0b013e3181bb05bbeng
dcterms.referencesCongreso de Colombia. LEY 1438 DE 2011 [Internet]. [cited 2019 Aug 4]. Available from: http://extwprlegs1.fao.org/docs/pdf/col132763.pdfspa
dcterms.referencesCongreso de Colombia. ley 1392 del 2010 [Internet]. [cited 2019 Aug 4]. Available from: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/DE/DIJ/ley-1392-de-2010.pdfeng
dcterms.referencesCantillo J, Rojas W. Enfermedad de Fabry. Med Clin (Barc). 2014;39(2):206–206.spa
dcterms.referencesTrujillo NM. Retos de la Investigación en Sistemas y Servicios de Salud. Cienc e Innov en Salud. 2014;2(1):46–51.spa
dcterms.referencesCristina I, Bermeo S. Pacientes En Lista De Trasplante Y Post- Trasplante Renal En Fundación Cardioinfantil. 2015;spa
dcterms.referencesRAE. Diccionario de la Real Academia Española - Cromosoma | Definición de cromosoma - Diccionario de la lengua española - Edición del Tricentenario [Internet]. [cited 2019 Feb 13]. Available from: https://dle.rae.es/?id=BLH224Espa
dcterms.referencesGriffiths AJ, Miller JH, Suzuki DT, Lewontin RC, Gelbart WM. Sex chromosomes and sex-linked inheritance. W. H. Freeman; 2000.eng
dcterms.referencesHow many chromosomes do people have? - Genetics Home Reference - NIH [Internet]. [cited 2019 Aug 17]. Available from: https://ghr.nlm.nih.gov/primer/basics/howmanychromosomeseng
dcterms.referencesAlliance G, Screening, Services TNY-M-AC for G and N. Genética [Internet]. Genetic Alliance; 2009 [cited 2019 Aug 5]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK132198/eng
dcterms.referencesWhat are lysosomes? Parts of a cell - Biology - Quatr.us Study Guides [Internet]. [cited 2019 Aug 17]. Available from: https://quatr.us/biology/lysosomes-cell-biology.htmeng
dcterms.referencesCooper GM. Lysosomes. Sinauer Associates; 2000.eng
dcterms.referencesAlberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. The Compartmentalization of Cells. 2002 [cited 2019 Aug 5]; Available from: https://www.ncbi.nlm.nih.gov/books/NBK26907/eng
dcterms.referencesBoustany R-MN. Lysosomal storage diseases--the horizon expands. Nat Rev Neurol [Internet]. 2013;9(10):583–98. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23938739eng
dcterms.referencesStulnig T. Lysosomale speicherkrankheiten. Austrian J Clin Endocrinol Metab. 2011;4(2):22–6.eng
dcterms.referencesMehta A, Beck M, Sunder-Plassmann G. Fabry Disease [Internet]. Fabry Disease: Perspectives from 5 Years of FOS. Oxford PharmaGenesis; 2006 [cited 2017 Jan 24]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21290683eng
dcterms.referencesPlatt FM, Boland B, van der Spoel AC. Lysosomal storage disorders: The cellular impact of lysosomal dysfunction. J Cell Biol. 2012;199(5):723–34.eng
dcterms.referencesGiugliani R, Brusius-Facchin A-C, Pasqualim G, Leistner-Segal S, Riegel M, Matte U. Current molecular genetics strategies for the diagnosis of lysosomal storage disorders. Expert Rev Mol Diagn [Internet]. 2016;16(1):113–23. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26567866eng
dcterms.referencesGLA gene - Genetics Home Reference - NIH [Internet]. [cited 2019 Aug 5]. Available from: https://ghr.nlm.nih.gov/gene/GLA#locationeng
dcterms.referencesFabry Disease - GeneReviews® - NCBI Bookshelf metaanalisis.eng
dcterms.referencesGrzeschik KH, Grzeschik AM, Banhof S, Romeo G, Siniscalco M, van Someren H, et al. X-linkage of human -galactosidase. Nat New Biol [Internet]. 1972 Nov 8 [cited 2017 Jan 24];240(97):48–50. Available from: http://www.ncbi.nlm.nih.gov/pubmed/4508394eng
dcterms.referencesCalhoun DH, Bishop DF, Bernstein HS, Quinn M, Hantzopoulos P, Desnick RJ. Fabry disease: isolation of a cDNA clone encoding human alpha-galactosidase A. Proc Natl Acad Sci U S A. 1985;82(November):7364–8.eng
dcterms.referencesBishop DF, Calhoun DH, Bernstein HS, Hantzopoulos P, Quinn M, Desnick RJ. Human alpha-galactosidase A: nucleotide sequence of a cDNA clone encoding the mature enzyme. Proc Natl Acad Sci U S A [Internet]. 1986;83(13):4859–63. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=323842&tool=pmcentrez&rendertype=abstracteng
dcterms.referencesBishop DF, Kornreich R, Desnick RJ. Structural organization of the human alpha-galactosidase A gene: further evidence for the absence of a 3’ untranslated region. Proc Natl Acad Sci U S A. 1988;85(11):3903–7.eng
dcterms.referencesDavies JP, Winchester BG, Malcolm S. Sequence variations in the first exon of alpha-galactosidase A. J Med Genet [Internet]. 1993;30(8):658–63. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1016494&tool=pmcentrez&rendertype=abstracteng
dcterms.referencesNovo FJ, Kruszewski A, Macdermot KD, Goldspink G, Górecki DC. Editing of human ??-galactosidase RNA resulting in a pyrimidine top purine conversion. Nucleic Acids Res. 1995;23(14):2636–40.eng
dcterms.referencesBernstein HS, Bishop DF, Astrin KH, Kornreich R, Eng CM, Sakuraba H, et al. Fabry disease: six gene rearrangements and an exonic point mutation in the alpha-galactosidase gene. J Clin Invest. 1989;83(21):1390–9.eng
dcterms.referencesMatsuzawa F, Aikawa S, Doi H, Okumiya T, Sakuraba H. Fabry disease: correlation between structural changes in alpha-galactosidase, and clinical and biochemical phenotypes. Hum Genet [Internet]. 2005;117(4):317–28. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15924232eng
dcterms.referencesAsociación Colombiana de Medicina Interna. JP, Cantillo J de J. Acta médica colombiana : AMC : órgano de la Asociación Colombiana de Medicina Interna. [Internet]. Vol. 34, Acta Medica Colombiana. Asociación Colombiana de Medicina Interna; 2009 [cited 2019 Aug 17]. 140–151 p. Available from: http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0120-24482009000300009spa
dcterms.referencesANDERSON W. a Case of “Angeio‐Keratoma.” Br J Dermatol. 1898;10(4):113–7.eng
dcterms.referencesFabry J. Ein Beitrag zur Kenntniss der Purpura haemorrhagica nodularis (Purpura papulosa haemorrhagica Hebrae) [A contribution to knowledge on the purpura haemorrhagica nodularis (purpura papulosa haemorrhagica Hebrae)]. Arch Dermatol Syph. 1898;43(1):187–200.eng
dcterms.referencesFabry H, Mehta AB, Beck M (Michael), Sunder-Plassmann G. Fabry disease : perspectives from 5 years of FOS. PharmaGenesis; 2006. 423 p.eng
dcterms.referencesUribe A, Mateus HE, Prieto JC, Palacios MF, Ospina SY, Pasqualim G, et al. Identification of mutations in Colombian patients affected with Fabry disease. Gene [Internet]. 2015;574(2):325–9. Available from: http://dx.doi.org/10.1016/j.gene.2015.08.018eng
dcterms.referencesEng CM, Fletcher J, Wilcox WR, Waldek S, Scott CR, Sillence DO, et al. Fabry disease: Baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis. 2007;30(2):184–92.eng
dcterms.referencesLaney D a, Peck DS, Atherton AM, Manwaring LP, Christensen KM, Shankar SP, et al. Fabry disease in infancy and early childhood: a systematic literature review. Genet Med [Internet]. 2014;17(August):1–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25232851eng
dcterms.referencesLaney DA, Bennett RL, Clarke V, Fox A, Hopkin RJ, Johnson J, et al. Fabry disease practice guidelines: Recommendations of the national society of genetic counselors. J Genet Couns. 2013;22(5):555–64.eng
dcterms.referencesR ED, Gomaa H, Rp C, Se C, Bazan R, Barretti P, et al. Enzyme replacement therapy for Anderson-Fabry disease ( Review ). 2016;(7).eng
dcterms.referencesHernberg-Ståhl E. Organization and technical aspects of FOS – the Fabry Outcome Survey [Internet]. Fabry Disease: Perspectives from 5 Years of FOS. Oxford PharmaGenesis; 2006 [cited 2017 Jan 26]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21290693eng
dcterms.referencesBeck M. Demographics of FOS – the Fabry Outcome Survey [Internet]. Fabry Disease: Perspectives from 5 Years of FOS. Oxford PharmaGenesis; 2006 [cited 2017 Jan 25]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21290679eng
dcterms.referencesNCBI Protein Database. Alpha-galactosidase [Pseudopedobacter saltans DSM 12145] - Protein - NCBI [Internet]. [cited 2019 Aug 5]. Available from: https://www.ncbi.nlm.nih.gov/protein/ADY53117.1eng
dcterms.referencesBrady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L. Enzymatic Defect in Fabry’s Disease. N Engl J Med [Internet]. 1967 May 25;276(21):1163–7. Available from: http://dx.doi.org/10.1056/NEJM196705252762101eng
dcterms.referencesSmith M. Fabry ’ s Disease : Alpha-Galactosidase Deficiency. 167:5–6.eng
dcterms.referencesWinchester B, Young E. Biochemical and genetic diagnosis of Fabry disease [Internet]. Fabry Disease: Perspectives from 5 Years of FOS. Oxford PharmaGenesis; 2006 [cited 2017 Jan 28]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21290697eng
dcterms.referencesWang AM, Desnick RJ. Structural organization and complete sequence of the human alpha-N-acetylgalactosaminidase gene: homology with the alpha-galactosidase A gene provides evidence for evolution from a common ancestral gene. Genomics [Internet]. 1991 May [cited 2017 Jan 28];10(1):133–42. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1646157eng
dcterms.referencesLemansky P, Bishop DF, Desnick RJ, Hasilik A, von Figura K. Synthesis and processing of alpha-galactosidase A in human fibroblasts. Evidence for different mutations in Fabry disease. J Biol Chem [Internet]. 1987 Feb 15 [cited 2017 Jan 28];262(5):2062–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/3029062eng
dcterms.referencesKiharali H, Serizawas S, Lis Y. DEFICIENCY IN URINE OF PATIENTS AFFECTED WITH CEREBROSIDE SULFATASE Bio : 1985;260(3):1867–71.eng
dcterms.referencesSchiffmann R, Kopp JB, Austin HA, Sabnis S, Moore DF, Weibel T, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA [Internet]. 2001 Jun 6 [cited 2017 Jan 29];285(21):2743–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11386930eng
dcterms.referencesBiegstraaten M, Arngrímsson R, Barbey F, Boks L, Cecchi F, Deegan PB, et al. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. Orphanet J Rare Dis [Internet]. 2015;10:36. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4383065&tool=pmcentrez&rendertype=abstracteng
dcterms.referencesEng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, et al. Safety and Efficacy of Recombinant Human α-Galactosidase A Replacement Therapy in Fabry’s Disease. N Engl J Med [Internet]. 2001 Jul 5 [cited 2017 Jan 29];345(1):9–16. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11439963eng
dcterms.referencesHoffmann BB. Fabry disease: recent advances in pathology, diagnosis, treatment and monitoring. Orphanet J Rare Dis. 2009;4:21.eng
dcterms.referencesCalzada C, De F, Madroñero M, Pascual Gómez-Moreno I, Tutora I, Belén :, et al. ENFERMEDAD DE FABRY: REVISIÓN BIBLIOGRÁFICA Y ESTUDIO DE UTILIZACIÓN.spa
dcterms.referencesSpada M, Kasper D, Pagliardini V, Biamino E, Giachero S, Porta F. Metabolic progression to clinical phenotype in classic Fabry disease. Ital J Pediatr [Internet]. 2017;10–2. Available from: http://dx.doi.org/10.1186/s13052-016-0320-1eng
dcterms.referencesMehta A, Widmer U. Natural history of Fabry disease [Internet]. Fabry Disease: Perspectives from 5 Years of FOS. Oxford PharmaGenesis; 2006 [cited 2017 Jan 29]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21290671eng
dcterms.referencesDiagnóstico de la enfermedad de fabry - Cardiopatias Familiares [Internet]. [cited 2019 Aug 17]. Available from: http://cardiopatiasfamiliares.es/diagnostico-la-enfermedad-fabry/eng
dcterms.referencesHoffmann B, Schwarz M, Mehta A, Keshav S. Gastrointestinal Symptoms in 342 Patients With Fabry Disease: Prevalence and Response to Enzyme Replacement Therapy. Clin Gastroenterol Hepatol. 2007;5(12):1447–53.eng
dcterms.referencesSodi A, Ioannidis AS, Mehta A, Davey C, Beck M, Pitz S. Ocular manifestations of Fabry’s disease: Data from the Fabry Outcome Survey. Br J Ophthalmol. 2007;91(2):210–4.eng
dcterms.referencesCornea verticillata [Internet]. [cited 2019 Aug 17]. Available from: https://webeye.ophth.uiowa.edu/eyeforum/atlas/pages/Verticillata/index.htmeng
dcterms.referencesRamaswami U. Update on role of agalsidase alfa in management of Fabry disease. Drug Des Devel Ther. 2011;(5):155–73.eng
dcterms.referencesEchevarria L, Benistan K, Toussaint A, Dubourg O, Hagege AA, Eladari D, et al. X-chromosome inactivation in female patients with Fabry disease. Clin Genet. 2016;89(1):44–54.eng
dcterms.referencesCairns T, Müntze J, Gernert J, Spingler L, Nordbeck P, Wanner C. Hot topics in Fabry disease. Postgrad Med J [Internet]. 2018;postgradmedj-2018-136056. Available from: http://pmj.bmj.com/lookup/doi/10.1136/postgradmedj-2018-136056eng
dcterms.referencesGarcía-Trabanino R, Badilla-Porras R, Carazo K, Courville K, de Luna E, Lemus P, et al. Consenso del Grupo Centroamericano y del Caribe para el Estudio y Tratamiento de la Enfermedad de Fabry. Nefrol Latinoam [Internet]. 2017 Jan 1 [cited 2019 Aug 7];14(1):27–38. Available from: https://www.sciencedirect.com/science/article/pii/S2444903216300038eng
dcterms.referencesCHMP. ANEXO I FICHA TÉCNICA O RESUMEN DE LAS CARACTERÍSTICAS DEL PRODUCTO [Internet]. [cited 2019 Aug 17]. Available from: https://www.ema.europa.eu/en/documents/product-information/replagal-epar-product-information_es.pdfspa
dcterms.referencesSmid BE, Van Der Tol L, Cecchi F, Elliott PM, Hughes DA, Linthorst GE, et al. Uncertain diagnosis of Fabry disease: Consensus recommendation on diagnosis in adults with left ventricular hypertrophy and genetic variants of unknown significance. Int J Cardiol [Internet]. 2014;177(2):400–8. Available from: http://dx.doi.org/10.1016/j.ijcard.2014.09.001eng
dcterms.referencesKeating GM, Simpson D. A Review of its Use in the Management of Fabry Disease. Drugs. 2007;67(3):435–55.eng
dcterms.references(EMA) EMA. Cetuximab; Erbitux®. Anexo I: Ficha técnica o resumen de las características del producto. Agencia Eur Medicam [Internet]. 2014;1–33. Available from: ec.europa.eu/health/documents/community.../anx_130850_es.pdfspa
dcterms.referencesMartín AL. Presentación de la guía 2018 [Internet]. [cited 2019 Feb 14]. Available from: https://www.svneurologia.org/wordpress/wp-content/uploads/2018/03/Guía-ictus-isquemico-agudo-2018.pdfspa
dcterms.referencesPaís N. GUÍA DE PRÁCTICA CLÍNICA DE DIAGNÓSTICO, TRATAMIENTO Y REHABILITACIÓN DEL EPISODIO AGUDO DE ATAQUE CEREBROVASCULAR ISQUÉMICO, EN POBLACIÓN MAYOR DE 18 AÑOS [Internet]. 2015 [cited 2019 Feb 14]. Available from: http://gpc.minsalud.gov.co/gpc_sites/Repositorio/Conv_637/GPC_acv/GPC_ACV_Version_Final_Completa.pdfspa
dcterms.referencesGuía de práctica clínica Hipertensión arterial primaria (hta) 2013-Guía No. 18 [Internet]. [cited 2019 Feb 14]. Available from: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/INEC/IETS/GPC_Completa_HTA.pdfspa
dcterms.referencesefectos de la suspension de IECA y ARAII en enfermedad renal cronica avanzada. [cited 2019 Feb 14]; Available from: http://www.revistanefrologia.com/es-pdf-X0211699512001160spa
dcterms.referencesLewis JRP, Gibson PH. Bilateral hip replacement in three patients with lysosomal storage disease: Mucopolysaccharidosis type IV and Mucolipidosis type III. J Bone Jt Surg [Br] [Internet]. 2010 [cited 2019 Aug 14];92(2):92–289. Available from: https://online.boneandjoint.org.uk/doi/pdf/10.1302/0301-620X.92B2.23104eng
dcterms.referencesSelthofer-Relatic K. Case Report Time of Anderson-Fabry Disease Detection and Cardiovascular Presentation. 2018; Available from: https://doi.org/10.1155/2018/6131083eng
dcterms.referencesEl Dib R, Gomaa H, Carvalho RP, Camargo SE, Bazan R, Barretti P, et al. Enzyme replacement therapy for Anderson-Fabry disease. Cochrane Database Syst Rev. 2016;2016(7).eng
dcterms.referencesZhou C, Huang J, Cui G, Zeng H, Wen Wang D, Zhou Q. Identification of a novel loss-of-function mutation of the GLA gene in a Chinese Han family with Fabry disease. Available from: https://doi.org/10.1186/s12881-018-0734-2eng
dcterms.referencesLiao HC, Hsu TR, Young L, Chiang CC, Huang CK, Liu HC, et al. Functional and biological studies of α-galactosidase A variants with uncertain significance from newborn screening in Taiwan. Mol Genet Metab. 2018 Feb 1;123(2):140–7eng
dcterms.referencesLavalle L, Thomas AS, Beaton B, Ebrahim H, Reed M, Ramaswami U, et al. Phenotype and biochemical heterogeneity in late onset Fabry disease defined by N215S mutation. PLoS One. 2018 Apr 1;13(4).eng
sb.sedeSede Barranquillaspa
sb.programaMaestría en Genéticaspa
dc.rights.accessrightsinfo:eu-repo/semantics/restrictedAccessspa
oaire.versioninfo:eu-repo/semantics/acceptedVersionspa
dc.type.driverOtherspa


Ficheros en el ítem

Thumbnail
Thumbnail
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 Internacional